Prezista and Prezcobix

Darunavir contains a sulfa component and should be used with caution by people with known sulfonamide allergy. Most common side effects may include diarrhea, nausea, headache, rash, vomiting, and abdominal pain. While very rare, severe rash can be accompanied by fever and/or elevations of liver enzymes, and can be life-threatening. Seek immediate medical attention. IRIS (immune reconstitution inflammatory syndrome) may occur as the immune system regains strength; signs and symptoms from previous infections may occur soon after HIV treatment is initiated. Report symptoms of illness, such as shingles or TB, to a health care provider. Protease inhibitors can cause increased risk for bleeding in hemophiliacs. Measure liver function before starting darunavir and then monitor. No dose adjustment necessary for darunavir with mild to moderate liver disease.

Tybost is not interchangeable with Norvir. Do not take with alfuzosin, dronedarone, ergot derivatives, ivabradine, lomitapide, lurasidone, naloxegol, pimozide, triazolam, oral midazolam, ranolazine, rifampin, Revatio, St. John’s wort, or Zepatier. Do not use lovastatin or simvastatin, or co-formulations. Alternatives are atorvastatin and rosuvastatin (dose of either should not exceed 20 mg per day). Not recommended with avanafil, rifapentine, rivaroxaban, or salmeterol. Erectile dysfunction drugs should not exceed 10 mg Cialis or 2.5 mg Levitra per 72 hours, or 25 mg Viagra per 48 hours. Titration or decreased dose may be needed for buspirone, diazepam, estazolam, and zolpidem. Therapeutic drug monitoring is recommended for amiodarone, bepridil, disopyramide, flecainamide, systemic lidocaine, mexiletine, propafenone, and quinidine. Tell your provider or pharmacist about all medications, herbals, and supplements you are taking or thinking of taking, prescribed or not, as there are many other drug interactions not listed here.

Prezista: Not recommended with everolimus, or ticagrelor, or with irinotecan. Monitoring of clonazepam, phenytoin, and phenobarbital is recommended. Tramadol dose decrease may be needed. Monitor therapeutic effects and adverse reactions with use of some analgesics, such as fentanyl and oxycodone. Reducing dose of rifabutin is recommended. Pitavastatin may be used with no dose adjustment, but pravastatin should be used with caution and started at the lowest dose possible. Monitor for increased side effects from these medications. Reduce clarithromycin dose by 50–75% in kidney impairment. Isavuconazole, posaconazole, ketoconazole, and itraconazole should be used with caution (maximum dose is 200 mg per day for ketoconazole and itraconazole). Voriconazole should not be used unless the benefits outweigh the risks. Effectiveness of oral contraceptives may be decreased. Increases the exposure of nasal and inhaled fluticasone and budesonide, as well as systemic corticosteroids ciclesonide, betamethasone, dexamethasone, methylprednisolone, mometasone, and triamcinolone. Use alternative corticosteroid and monitor for signs of Cushing’s syndrome. Beclomethasone, prednisolone, and prednisone as alternative corticosteroids may be considered. Monitoring is recommended for co-administration with drospirenone. Monitoring is recommended with buprenorphine, buprenorphine/naloxone, and methadone.

Prezcobix: Do not take with carbamazepine, dexamethasone, phenytoin, or phenobarbital, or with colchicine (in people with kidney or liver impairment). Not recommended to be taken with betamethasone, budesonide, ciclesonide, everolimus, fluticasone, Mavyret, methylprednisolone, mometasone, rifapentine, salmeterol, ticagrelor, triamcinolone, or voriconazole. Monitor for lack of virologic response when eslicarbazepine or oxcarbazepine is needed. Initiation or dose adjustments of insulin or oral hypoglycemic medications may be required for some individuals. Apixaban dose may need to be adjusted.

Darunavir is found in the single-tablet regimen Symtuza (see that page). The DHHS recommendation is “in part because of greater tolerability” with the integrase inhibitor medications. Pregnant individuals can voluntarily enroll in the Antiretroviral Pregnancy Registry through their provider; go to apregistry.com.

Dr. Melanie Thompson:

Darunavir is coformulated in Symtuza. It has a high genetic barrier to resistance, meaning that a few missed doses are not likely to select for resistant viruses. But its Achilles heel is that it requires boosting with ritonavir or cobicistat. That is one of the key reasons that darunavir-based regimens are not recommended for initial therapy for most people. A large observational study found darunavir to be associated with higher cardiovascular risk than atazanavir. Ritonavir should be used as a booster in pregnancy. Boosted darunavir given with TAF or TDF and FTC or 3TC may be used when HIV is acquired after cabotegravir PrEP exposure and when an INSTI genotype result is not available at the time of initiation of therapy. Keep in mind that pill burden is important, and coformulated regimens may be preferable if cost allows.

Activist Joey Wynn:

Once a strong first line option, now it is relegated to a few minor situations for a very select few. Boosters are no longer acceptable as a first line defense in my opinion, so this is a trusted option for heavily treatment-experienced people in need of something powerful.